MONROVIA, Calif. and HANGZHOU, China, Oct. 13 /PRNewswire-FirstCall/-- Niusule Biotech Corp. (“Niusule” or the “Company”) (OTC Bulletin Board: NIUS), a leading U.S.-based biotech company focused on developing and selling nutritional products for children, today announced that the Company successfully launched
On September 16, 2009, Niusule began selling its branded “Niusule Gummy Bears” at leading department stores, including Hangzhou Tower, the biggest shopping mall in Zhejiang province, Hangzhou Jiebai Group Company Limited and Lianhua Supermarket. The Company’s leading PlantFusion protein products have been sold in Hangzhou Tower since July 2009. Bearing “Niusule” brand, the Company’s Gummy Bears are manufactured in the U.S. by Santa Cruz Nutritionals. Unlike the traditional candy Gummy Bears, Niusule’s Gummy Bears are both a multivitamin formula and a formula fortified with Vitamin D, Calcium, and Phosphorus. The Company’s R&D team has also modified the formula to make the flavors more suitable and appealing to the Chinese consumers.
In March of this year, Niusule obtained a business license from Hangzhou Administration for Industry and Commerce to establish Niusule Bioengineering (Hangzhou) Co. Ltd., a new wholly-owned subsidiary of Niusule Biotech Corp to market and sell its products in China. Gummy Bears are very popular products in China and have acquired a certain degree of recognition among Chinese parents. The Company applied for the Gummy Bears trademark registration with China Trademark Office on August 28, 2009. The first shipment of Gummy Bears received Sanitary Certificate from Entry-Exit Inspection and Quarantine of People’s Republic of China in September 2009. As such, the Company has been approved as a wholesaler and retailer for its branded health food products in China. Niusule is also in talks with qualified distributors in other provinces and expects to enter new regional markets in China in the near term through distribution partnerships.
“We are excited to announce that we have been approved to market and sell Niusule Gummy Bears in China,” commented Ms. Qinghua Hu, CEO and CFO of Niusule Biotech Corp. “According to data from China Population & Development Research Center, there are about 251 million children under the age of 14 in China. In light of the recent health concerns, Chinese parents are keen on obtaining high-quality, safe, and nutritional products for their children. We are confident that our Gummy Bears, manufactured in the United States under Good Manufacturing Processes ("GMPs") for dietary supplements will capture this growing demand in China. We plan to expand our distribution channel by increasing our sales force and partnering with distributors, we plan to sell Gummy Bears through 50 shopping centers and super markets in China by November 2009. We believe our aggressive expansion strategy combined with growing demand will result in robust revenue growth in the near term.”
About Niusule Biotech Corp.
Niusule is engaged in the business of manufacturing, marketing and selling health food and related products. The Company manufactures mature health food products, including PlantFusion and Gummy Bears, in the United States and markets and distributes these products to Chinese consumers. Niusule also maintains a strong focus on biotechnology R&D and is committed to becoming a leading player in China’s rapidly growing health food and bioengineering industry. The Company’s products are cultivated from natural plants and improved in flavors through R&D program with the Zhejiang University in China. Niusule’s products are manufactured in strict accordance with international standards. For more information, contact CCG Investor Relations directly or go to Niusule’s website at http://www.niusule.com.
Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such factors or to announce publicly the results of any revisions of the forward-looking statements contained herein to reflect future events or developments. You are urged to consider these factors care in evaluating the forward-looking statements herein and are cautioned not to place undue reliance on such forward-looking statements, which are qualified in their entirety by this cautionary statement. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company’s expectations.
SOURCE Niusule Biotech Corp.
Subscribe to our Free Newsletters!
Cachexia refers to severe muscle and fat loss, anorexia and marked weight loss due to an underlying ...
Exotropia or outward eye deviation is a form of squint. Proper evaluation and timely intervention ...
Glaucoma is a group of disorders involving the optic nerve, often associated with a rise in ...View All